Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $40
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsPrice Target
Keybanc analyst Paul Knight maintains Castle Biosciences (NASDAQ:CSTL) with a Overweight and raises the price target from $35 to $40.
Keybanc analyst Paul Knight maintains Castle Biosciences (NASDAQ:CSTL) with a Overweight and raises the price target from $35 to $40.